Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of securities of Aquestive Therapeutics, Inc. for the period between June 16, 2025, and January 8, 2026, due to alleged misleading statements regarding the company's New Drug Application for Anaphylm [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that Aquestive made false and/or misleading statements and failed to disclose the true state of its New Drug Application for Anaphylm, particularly regarding the human factors involved in the use of its sublingual film [5]. - Investors who purchased Aquestive securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Interested parties can join the class action by visiting the provided link or contacting Phillip Kim, Esq. for more information [3][6]. - A lead plaintiff must move the Court by May 4, 2026, to represent other class members in directing the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - Hims & Hers Health Inc. has seen a significant stock price increase due to renewed investor interest following analyst upgrades and a renewed partnership with Novo Nordisk [1]. Group 1: Stock Performance - Hims & Hers stock rose by 10.27% to close at $25.88, marking the third consecutive day of gains [1]. - The stock is among the top 10 movers in the market today [1]. Group 2: Analyst Upgrades - Deutsche Bank, Citigroup, and Bank of America have all raised their price targets for Hims & Hers to $28, $24, and $23, respectively, from previous targets of $25, $13.25, and $12.50 [2]. - Citigroup and Bank of America upgraded their ratings to "neutral" from "sell" and "underperform," respectively, while Deutsche Bank maintained a "neutral" stance [4]. Group 3: Partnership with Novo Nordisk - Hims & Hers renewed its partnership with Novo Nordisk, agreeing to discontinue the sale and marketing of compounded versions of Novo's drugs, Wegovy and Ozempic [5]. - The company will only provide access to its own GLP-1 products when FDA-approved versions do not meet customer needs and if deemed clinically necessary by a provider [5].

Core Viewpoint - A class action has been filed against Soleno Therapeutics for allegedly misleading investors regarding the safety and efficacy of its drug DCCR during its Phase 3 clinical trial [1][2]. Group 1: Allegations and Concerns - The complaint alleges that Soleno failed to disclose significant safety concerns related to DCCR, including issues of excess fluid retention in trial participants [2]. - It is claimed that the administration of DCCR posed greater safety risks than disclosed, leading to materially lower commercial viability and undisclosed risks of adverse events post-launch [2]. - The allegations include that the company misrepresented the likelihood of patient discontinuation, lower adoption rates, and potential regulatory and reputational fallout [2]. Group 2: Impact on Stock Price - Following the release of a report by Scorpion Capital on August 15, 2025, which detailed issues with Soleno's clinical trial and safety concerns, the stock price fell nearly 12% over two trading days [3]. - After a patient death linked to DCCR was disclosed in a Form 8-K on September 10, 2025, the stock experienced a nearly 19% decline over two trading days [4]. - On November 4, 2025, after reporting third-quarter financial results, Soleno's stock dropped approximately 27% in one day, from nearly $64 to about $47 per share, attributed to concerns raised by the Scorpion Capital report [5].

Core Viewpoint - The Portnoy Law Firm is advising investors of Aquestive Therapeutics, Inc. to join a class action lawsuit due to alleged misleading statements regarding the approval of their New Drug Application for Anaphylm, which led to significant stock price decline [1][3][4]. Group 1: Class Action Details - The class action lawsuit is on behalf of investors who purchased securities between June 16, 2025, and January 8, 2026 [1]. - Investors have until May 4, 2026, to file a lead plaintiff motion [1]. - The lawsuit claims that Aquestive misrepresented its progress towards FDA approval for Anaphylm, leading to a false impression of readiness for approval by the January 31, 2026, PDUFA date [3]. Group 2: Allegations and Impact - The lawsuit alleges that the FDA identified deficiencies in the NDA for Anaphylm, which prevented discussions on labeling and post-marketing commitments [3]. - Following the disclosure of these deficiencies on January 9, 2026, Aquestive's stock price fell by more than 37% [4]. - The firm emphasizes that for the FDA to grant approval, all identified deficiencies must be remedied, indicating a delay in the launch of Anaphylm [3].

Group 1 - The lawsuit against Franklin BSP Realty Trust, Inc. has been filed on behalf of investors who purchased securities between November 5, 2024, and February 22, 2026, alleging false and misleading statements regarding the company's prospects and dividend maintenance [1] - Franklin reported fourth quarter earnings per share of $0.12, missing consensus estimates by $0.16, and revenue of $81.12 million, compared to the consensus estimate of $93.65 million [1] - Following the announcement of disappointing financial results, Franklin's share price declined by $1.44, or approximately 14.2%, from $10.15 to $8.71 [1] Group 2 - Investors have until April 27, 2026, to seek the role of lead plaintiff in the class action lawsuit, with courts not considering applications filed after this deadline [1] - The lead plaintiff will oversee the litigation on behalf of the class and may influence key decisions, including litigation strategy and settlement [1] - Kirby McInerney LLP, the law firm handling the case, specializes in securities litigation and has achieved recoveries totaling billions of dollars for shareholders [1]

Core Insights - The company has undergone significant changes in leadership over the past couple of years, with new executives bringing fresh perspectives and initiatives [1] Group 1: Leadership Changes - The new CEO, Steven Basta, joined the company nearly a year ago and was attracted to the opportunity due to the potential of the company's product to significantly improve patient quality of life [1] Group 2: Company Mission - The primary focus of the company is to deliver effective therapies that enhance the quality of life for patients, which aligns with its mission in the healthcare sector [1]

Company Overview - Corcept Therapeutics Incorporated (NASDAQ:CORT) is a commercial-stage pharmaceutical company focused on developing treatments for serious disorders through cortisol modulation [5]. Financial Performance - For Q4 2025, Corcept reported revenue of $202.1 million, which was below the consensus estimate of $254.9 million [2]. - The full-year revenue for 2025 was reported at $761.4 million, falling short of the revised guidance range of $800 million to $850 million [2]. Prescription and Sales Growth - New prescriptions for Corcept's products increased by 61% year-over-year in 2025; however, actual tables sold only saw a 37% increase due to capacity constraints at the previous specialty pharmacy [3]. - Sales of Korlym were impacted during the transition to a new specialty pharmacy, Curant Rare, which began in November 2025 and was completed in January 2026 [3]. Future Guidance - The company provided revenue guidance for 2026 in the range of $900 million to $1 billion, indicating approximately 25% year-over-year growth at the midpoint [4]. - H.C. Wainwright has adjusted its price target for Corcept from $67 to $60, maintaining a Buy rating, reflecting a more cautious outlook for the Korlym franchise [4].

Ironwood Pharmaceuticals Conference Call Summary Company Overview - **Company**: Ironwood Pharmaceuticals (NasdaqGS:IRWD) - **Focus**: Gastrointestinal (GI) healthcare - **Key Products**: LINZESS (treatment for irritable bowel syndrome with constipation and chronic idiopathic constipation) and apraglutide (Phase III asset for short bowel syndrome with intestinal failure) [2][3] Key Points LINZESS Performance - **Sales Expectations**: LINZESS is projected to generate over $1.1 billion in U.S. net sales in 2026 [2] - **Demand Growth**: LINZESS has experienced high single-digit to low double-digit prescription demand volume growth, attributed to new patients transitioning from over-the-counter therapies [4] - **Pricing Strategy**: Adjustments made to LINZESS pricing in 2026 to eliminate inflationary rebate penalties, particularly in Medicaid [5][6] - **Market Position**: LINZESS remains a market leader, with 50% of its volume coming from Medicare, providing visibility into pricing for 2026 and beyond [7] Financial Guidance - **Adjusted EBITDA**: Expected to exceed $300 million in 2026, a more than 100% increase from $138 million in 2025 [15] - **Debt Management**: Plans to pay down $200 million in convertible notes and a portion of the outstanding credit facility by year-end, aiming for approximately $300 million in gross debt, around 1x adjusted EBITDA [16] Apraglutide Development - **Phase III Study**: A confirmatory Phase III study for apraglutide is set to begin in Q2 2026, targeting short bowel syndrome with intestinal failure [3][41] - **Clinical Data**: The primary endpoint of the Phase III study is a 24-week reduction in weekly parenteral support volume, with previous trials showing efficacy twice that of placebo [29] - **Regulatory Engagement**: Ongoing discussions with the FDA to confirm the results of the original STARS study and ensure alignment on trial design for the confirmatory study [40][41] Strategic Focus - **Maximizing Shareholder Value**: The company is focused on maximizing shareholder value through strategic reviews and prioritizing LINZESS and apraglutide development [19][20] - **Commercial Strategy**: Leveraging experience from LINZESS to prepare for the commercial launch of apraglutide, with a focus on the U.S. market and potential partnerships in select regions [60][63] Pediatric Market Opportunity - **Expanded Label**: LINZESS has received approvals for pediatric use, contributing to demand growth, although not significantly altering overall demand trends [10][11] Market Dynamics - **Healthcare Changes**: Navigating legislative changes such as the Medicaid AMP cap repeal and Medicare Part D redesign, which have impacted pricing and rebates [6][8] Future Outlook - **Execution Focus for 2026**: The company aims to execute its strategies effectively, focusing on LINZESS and the STARS 2 study while managing debt [66][70] Additional Insights - **Physician Feedback**: Positive feedback from physicians regarding LINZESS primarily revolves around its pain management benefits, which have been highlighted in recent studies [12][13] - **Patient Autonomy**: In ongoing trials, one in five patients has achieved enteral autonomy, indicating significant clinical benefits from apraglutide therapy [53] This summary encapsulates the key discussions and insights from the Ironwood Pharmaceuticals conference call, highlighting the company's strategic priorities, financial expectations, and product development plans.

Core Insights - Eli Lilly and Company (NYSE: LLY) is enhancing patient access to tirzepatide medications, including Zepbound and Mounjaro, through new Medicare initiatives [1][2][3] Group 1: Medicare Program Details - Starting January 1, 2027, tirzepatide treatments will be available through Medicare Part D plans, with out-of-pocket costs capped at $50 per month after the deductible is met [1] - The Medicare GLP-1 Bridge Model will be implemented from July 1, 2026, allowing eligible beneficiaries to access these medications for no more than $50 per month with no deductible during the initial six-month period [2] - For the 2027 rollout, cost-sharing will be limited to $245 per month plus a dispensing fee, providing immediate financial relief compared to traditional pricing structures [2] Group 2: Collaboration and Education Efforts - Eli Lilly is collaborating with health plans and providers to educate patients about their specific plan options, as some basic Medicare Part D plans may have varying cost-sharing requirements [3] - State Medicaid programs are invited to apply for participation starting May 1 on a rolling basis [3] Group 3: Company Overview - Eli Lilly discovers, develops, manufactures, and markets human pharmaceutical products in the US, Europe, China, Japan, and internationally [3]

Core Viewpoint - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Corcept Therapeutics Incorporated due to significant losses following regulatory issues with the FDA [1][5]. Group 1: Investigation Background - On December 31, 2025, Corcept disclosed that the FDA issued a Complete Response Letter regarding its new drug application for relacorilant, leading to a share price decline of approximately 50% [3]. - On January 30, 2026, a corrected CRL revealed that the FDA had previously informed Corcept of concerns regarding its clinical development program, resulting in another double-digit decline in share price [4]. Group 2: Legal and Investor Support - Johnson Fistel is assessing whether Corcept complied with federal securities laws, inviting affected investors to join the investigation [5]. - The firm offers no-cost consultations for investors who suffered losses from their investment in Corcept stock [2]. Group 3: Firm Background - Johnson Fistel, PLLP is a nationally recognized law firm specializing in shareholder rights, with a history of recovering significant amounts for clients [6][7].